Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

eement, including our agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-Q for the quarter ended March 31, 2007. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com

Contact

Regeneron Pharmaceuticals, Inc.
Charles Poole
Vice President, Investor Relations
1-914-345-7640
charles.poole@regeneron.com
or
Lauren Tortorete
Media Relations
1-212-845-5609
ltortorete@biosector2.com


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
(Date:1/22/2015)...  Bio-Techne Corporation (NASDAQ: TECH ) announced today ... the new Simple Plex platform through its Proteins Platform ... re-branding of the previously acquired CyPlex instrument platform from ... transformative immunoassay technology which integrates an innovatively designed microfluidic ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... In work suggesting a new approach to treating polycystic kidney ... Children,s Hospital Boston were able to block the formation of ... model. Their findings, using a compound that inhibits a receptor ... online edition of the Journal of Clinical Investigation . ...
... PDII ) today announced that Nancy Lurker, the company,s chief ... Sciences Conference at 10:30 am ET on September 20, 2010 at ... may be accessed under the "Investor Relations" tab on the company,s ... 90 days. About PDI PDI ...
Cached Medicine Technology:A New Target in Polycystic Kidney Disease 2A New Target in Polycystic Kidney Disease 3
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... for America,s Health (TFAH) Executive Director Jeff Levi, Ph.D., will be ... and Pensions hearing on "Prevention and Public Health: The Key to ... The hearing will be held at 10 AM in room 192 ... "TFAH believes that a strong public health system and ...
... Joffe, and,Alan Buckey today filed an amendment to their ... The group previously filed a 13D,disclosing ownership of 11.4% ... 77 LasikPlus fixed-site laser vision correction centers in 33 ... founder and former Chairman and CEO of,LCAV. Craig ...
... TUESDAY, Dec. 9 (HealthDay News) -- Selenium, vitamin E ... cancer. , In findings that were released early because ... large randomized, controlled clinical trials showed the supplements failed ... seemed to indicate great promise -- particularly for selenium. ...
... deadliness of Alzheimer,s, report says , , TUESDAY, Dec. 9 ... fail to record severe dementia as a cause of death ... only points to a lack of knowledge about how dementia ... deadly illness, it suggests that deaths due to Alzheimer,s and ...
... Nonprofit Recognizes that Clean Energy Will Make Air Healthier to ... Dec. 9 The American Lung Association, a leader in ... of the Pickens Plan at a press conference today with ... American business leader and philanthropist. Developed by Mr. Pickens, the ...
... provide the public with timely government and regulatory information ... Dec. 9 The Association for the Advancement of ... providing wound care clinicians, regulators, health insurance payors and ... issues. The Wound Care Specialty Council (WocSpec) is a ...
Cached Medicine News:Health News:TFAH to Testify at Congressional HELP Committee Hearing on Prevention and Public Health on Dec. 10 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 3Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 4Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 5Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 6Health News:Selenium, Vitamins E and C Won't Prevent Prostate Cancer 2Health News:Selenium, Vitamins E and C Won't Prevent Prostate Cancer 3Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:American Lung Association Announces Support of Pickens Plan 2Health News:American Lung Association Announces Support of Pickens Plan 3Health News:American Lung Association Announces Support of Pickens Plan 4Health News:The Association for the Advancement of Wound Care has Created the Wound Care Specialty Council 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: